Purpose To determine whether a multivariate machine learning-based model using computer-extracted features of pretreatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer patients. Methods Institutional review board approval was obtained for this retrospective study of 288 breast cancer patients at our institution who received NAT and had a pre-treatment breast MRI. A comprehensive set of 529 radiomic features was extracted from each patient's pre-treatment MRI. The patients were divided into equal groups to form a training set and an independent test set. Two multivariate machine learning models (logistic regression and a support vector machine) based on imaging features were trained to predict pCR in (a) all patients with NAT, (b) patients with neoadjuvant chemotherapy (NACT), and (c) triple-negative or human epidermal growth factor receptor 2-positive (TN/HER2+) patients who had NAT. The multivariate models were tested using the independent test set, and the area under the receiver operating characteristics (ROC) curve (AUC) was calculated. Results Out of the 288 patients, 64 achieved pCR. The AUC values for predicting pCR in TN/HER+ patients who received NAT were significant (0.707, 95% CI 0.582-0.833, p < 0.002). Conclusions The multivariate models based on pre-treatment MRI features were able to predict pCR in TN/HER2+ patients.
Introduction
Neoadjuvant therapy (NAT) allows for early treatment of breast cancer, aiming to reduce tumor burden and allow patients to undergo breast-conserving surgery rather than mastectomy [1] [2] [3] [4] [5] [6] . One trial reported up to 23% of patients with primary operable breast cancer can have breast-conserving surgery instead of mastectomy if treated with neoadjuvant therapy [7] . However, response rates to NAT vary among patients and have been shown to depend on subtype [8] [9] [10] [11] [12] [13] [14] [15] [16] . In fact, up to 30% of patients may not respond to NAT [17] . These patients incur toxicities and costs of treatment but gain proportionally less benefit [7, 8] . Identifying a method to predict which breast cancer patients will achieve pCR and which will have residual invasive disease (RD) following NAT would allow for improved stratification of patients to more appropriate treatment regimens [18] .
Among other means of predicting response to NAT, such as using tumor stage and receptor status [19] , features extracted from pre-treatment MRI have shown promise for this purpose [8, 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] . Using MRI could provide a fast and non-invasive way to further stratify patients at no additional cost to patients who already require MRI as part of a standard preoperative workup for breast cancer. However, all prior studies evaluating this possibility analyzed relatively small cohorts (ranging from 11 patients [18] to 151 patients [25] ) and most did not use an independent dataset for validation. Furthermore, the methods used to determine response to NAT varied. While several studies [18, 21, 24, 26] used the response evaluation criteria in solid tumors (RECIST) [29] , others [20, 22] used pathologic assessment. Additionally, the definition of complete response among these papers differed considerably.
Our study builds on past research by showing a promising association between pre-treatment MRI characteristics and pCR in breast cancer, particularly in patients with TN/HER2+ tumors. Due to our larger dataset, we were able to create an independent validation cohort for each subpopulation. With this independent validation set, we were able to validate the work of previous studies [20] . Of particular interest, no prior studies have reported the prediction of pCR response in TN/ HER2+ patients using an independent test set. The extensive set of 529 features allowed for comprehensive analysis of different aspects of MRIs including size, shape, enhancement, and texture of tumors and the surrounding tissue.
Materials and methods

Patient population
In this retrospective institutional review board-approved study, we analyzed data for 288 patients treated with NAT.
To arrive at this cohort, we reviewed 1150 consecutive female invasive breast cancer patients without prior history of breast cancer, breast surgery (definitive or non-definitive), or breast cancer therapy, with available pre-treatment, preoperative bilateral MRI performed at Duke University Hospital between January 1, 2000 and March 23, 2014. Out of these patients, 374 were treated with NAT (including chemotherapy, endocrine, and anti-HER2neu therapies) according to medical histories and had sufficient data to establish pathologic response to NAT. To clearly distinguish between patients with pCR and those with residual invasive disease, patients with in situ carcinoma only following NAT were excluded (n = 15). Of the resulting 359 patients, 288 had all necessary MR sequences available and suitable for our image pre-processing steps. Details regarding patient exclusions can be found in Fig. 1 .
Pathology data collection
The pCR or pathological non-complete response (pNR) status of patients in our cohort was established using the following methods. First, pathology reports from the initial surgical intervention (mastectomy or lumpectomy) were reviewed and the tumor re-staging (ypTNM) information was collected. When a ypTNM stage was not reported, the complete pathology reports were reviewed. Then, the pCR/pNR status was identified according to the criteria in Table 1 . Ultimately, pCR was defined as having no remaining invasive or in situ disease in the breast or lymph nodes, and pNR was defined as any residual invasive disease in either breast or lymph nodes.
Additionally, patients whose treatment regimens included neoadjuvant chemotherapy (NACT), either alone or in addition to other neoadjuvant therapies (including endocrine or anti-HER2neu therapies), were identified from our cohort of 288 patients. The receptor status of these patients was determined from the clinical and immunohistochemical analysis of the tissue samples obtained from these patients.
Imaging data & annotation
For all patients, pre-treatment dynamic contrast-enhanced MR (DCE-MR) images were available with the following sequences: (a) T1-weighted fat-saturated pre-contrast sequence, (b) multiple (2-6) T1-weighted fat-saturated postcontrast sequences that were acquired following intravenous administration of a contrast agent, and (c) T1-weighted nonfat-saturated sequence. One of eight post-fellowship trained breast radiologists annotated each patient's images by placing a three-dimensional box around tumors in the subtracted sequence (obtained by subtracting the pre-contrast from the first post-contrast sequence).
Image Processing and feature extraction
The tumor mask was obtained by applying the fuzzy C-means algorithm [30] inside the annotation box created by the radiologists for each patient. Based on the masks extracted and the available sequences, we extracted 529 radiomic features [31] . These features include breast and fibroglandular tissue (FGT) volumetric features (5), tumor size and morphology (10), tumor enhancement (30), FGT enhancement (82), tumor enhancement texture (135), FGT enhancement texture (135), tumor enhancement variation (35) , FGT enhancement variation (34), spatial variation of tumor heterogeneity (4), and combination of tumor and FGT enhancement (18) . Any FGTrelated feature was extracted twice to include only one type of FGT mask at a time.
Model development and statistical analysis
The entire cohort of patients was divided to form training and test sets of equal size. All machine learning models were generated using the training set only. This model generation included feature selection and training two different classifiers using the selected features as follows. Using the entire training set, a stepwise multilinear regression-based feature selection procedure was used to select features (stepwisefit function in Matlab 2016b, The Mathworks, Natick, MA) for predicting pCR. The selected features were used to train a multivariate logistic regression classifier (fitglm function in Matlab 2016b) and a support vector machine classifier (fitcsvm and fitSVMposterior functions in Matlab 2016b). The trained models were used to predict pCR in the test set. The No remaining invasive or in situ disease in either breast or lymph nodes Any remaining invasive disease in breast or lymph nodes noted performance of each of the trained models was evaluated through analysis of the area under the receiver operating characteristics (ROC) curve (AUC). The AUC and its confidence intervals were calculated using the proc package in R [32] using the Delong method [33] . The output of the multivariate model was used as the covariate in a logistic regression model to determine the significance of its association with NAT. In addition to performing the feature selection and training classifiers for all patients in the training set, we repeated it for two additional subpopulations based on therapies received and receptor status in the training set: (a) patients who received NACT and (b) Triple-negative or HER2+ (TN/HER2+) patients who received NAT. We have not analyzed TN/HER2+ patients with NACT as a separate cohort because this group was almost identical to the second group analyzed (only one TN/HER2+ patient received NAT that did not include chemotherapy). The classifiers trained on these two subpopulations in the training set were evaluated in the corresponding subpopulations in the test set. Because we had two models per subpopulation, the significance level considered was (0.05/(3 × 2) = 0.0083) by Bonferroni correction. Additionally, the individual AUCs of the all the selected features (from the training set) were calculated in the test set to investigate specific prognostic features as an exploratory analysis.
Results
Characteristics of the study population
Characteristics of all patients are shown in , which is expected in these populations. Further details regarding the characteristics of the study population relevant to each task are shown in Table 2 . The distribution of pCR and pNR in different subsets of the study population and across the training and test sets is shown in Table 3 .
Performance of prognostic models
The accuracies of the trained multivariate models in terms of AUC are shown in Table 4 . The multivariate models (both SVM and logistic regression) were prognostic of pCR in TN/HER2+ patients that received neoadjuvant therapy (p < 0.002). The prognostic value of the model predicting pCR in the entire cohort was marginally significant (p = 0.01). Using the training set, a variable number of features were selected for the entire cohort and each of the subpopulations. In total, 12 unique features were selected for the three cohorts using the training set.
The results of our exploratory analysis using the 12 selected features are shown in Fig. 2 . Two features were selected for TN/HER2+ patients who received NAT. Among these features, a tumor-based feature (change_in_variance_ of_uptake) was selected for the subpopulation of all patients who received NAT as well as the TN/HER2+ subpopulation. This feature quantifies the change in variance of tumor uptake by finding the minimum ratio of the variances of tumor voxels in two consecutive time points. For this feature, lower values predict a higher chance of achieving pCR. This tumor-based feature had the highest AUC among the 12 features selected in all subpopulations evaluated. An additional feature, extracted using FGT, was also selected and found to be significant in TN/HER2+ patients who received NAT. This feature, 'SER_Partial_tissue_vol_cu_mm_T1,' is computed as a volumetric measure of FGT enhancement (extracted from T1 non-fat-saturated sequences) using the signal enhancement ratio of FGT voxels. For this feature, higher values predicted a lower chance of achieving pCR. Of all the features evaluated, 6 were extracted from tumor alone, 5 were extracted from FGT alone, and one was extracted from both tumor and FGT.
Discussion
In this study, we analyzed 288 breast cancer patients and demonstrated that multivariate machine learning models based on MRI features are able to predict pathologic complete response to neoadjuvant therapy in breast cancer. We selected important features from an initial set of 529 features using training data and subsequently developed multivariate machine learning models. We evaluated the performance of these models in our independent test set, validating their prognostic value in TN/HER+ patients.
Our study used a set of 529 MR features extracted from the pre-treatment breast MRIs of patients in our cohort. We used feature selection [34] to identify a smaller number of features (< 8) for further analysis. Models using less features (n = 2) performed better compared to models using a higher number of features (n = 7). The exploratory analysis showed three features that were independently prognostic of pCR in the test set. For each of our subpopulations, features extracted from tumor and FGT were selected to be included in our models and were combined to form a comprehensive set of features. Although Fan et al. used a similar combination of tumor and background parenchymal features to perform analyses, our study used the clinically preferred pathologic assessment to determine response rather than the RECIST criteria based on imaging [21] . While several studies use radiomic MRI features to monitor response [15, 18, 35, 36] , our goal was to use MRI to predict tumor response. Published studies with this goal are limited by small cohort sizes [18, 20-22, 24, 25] . Furthermore, most of these studies used RECIST to measure response [18, 21, 24, 25] , even though pCR is highly correlated with event-free survival and overall survival [1] . Studies using pathologic assessment to determine response have varying definitions of pCR [20, 22] . In some of these studies patients with positive lymph nodes [20, 22] , residual DCIS [20, 22] , or even residual invasive carcinoma in the breast [22] are categorized as having pCR. In an attempt to differentiate between NAT patients in a clinically relevant manner, we defined pCR as having no residual invasive or in situ carcinoma in the breast or lymph nodes [1] .
Our study is the first of this type to incorporate a broader definition of NAT. Our study included patients who received endocrine and anti-HER2neu therapy in the neoadjuvant setting, whether or not these patients received neoadjuvant chemotherapy (anthracycline, platinum, or taxane-based chemotherapy). However, in addition to the more inclusive analysis of all NAT patients (n = 288), we separately analyzed the sub-cohort of patients who received NACT (n = 269).
Due to our larger cohort, we were able to evaluate the specific group of TN/HER2+ patients who received NAT (only one patient in this cohort did not receive NACT, which is expected [37] [38] [39] [40] [41] [42] [43] ) separately. Furthermore, we were able to validate our findings for this subpopulation using an independent test set, which past studies [20] were unable to do. We found a significant association between our multivariate models and pCR in TN/HER2+ patients. These findings are important because TN/HER2+ patients achieve higher rates of pCR compared to HR+/HER2-cancers and have improved disease free and overall survival after a pCR [28, 38, 44, 45] . While there is no current method to predict pCR on an individual basis for TN/HER2+ 2+ patients, our study shows promise that pre-treatment MRI might serve this purpose.
Conclusion
While breast cancer patients who achieve pathologic complete response to neoadjuvant therapy have significant improvements in both event-free survival and overall survival, only 10-50% of patients achieve this level of response to NAT [46] . While patients not having a complete response may still derive benefit, their treatment is, by definition, sub-optimal. It is prudent to find effective means of predicting response to neoadjuvant therapy prior to initiating this treatment. Such a predictive tool would allow for early identification of non-responders, allowing for more personalized medical care. Our study used machine learning models that combined MRI-based features for this purpose. We found this method successfully predicted pCR in TN/ HER2+ patients who had NAT. Our findings highlight the potential use of pre-treatment breast MRI as a means to stratify breast cancer patients to more appropriate treatment regimens, allowing for more personalized care and improved quality of life.
